Takeaways from the most recent news in the technology and policies shaping healthcare.
The software running healthcare: EHRs, interoperability, AI, and automation, and where new tools actually move the needle versus add to the noise.
Health systems are deploying AI to translate medical jargon and explain treatment options, aiming to make patient visits more informed and collaborative.
Why it matters: Better-prepared patients could reshape the doctor visit, but only if AI education is accurate and keeps clinicians in control.
RAAPID's sponsored OnePass pitch claims audit-ready risk adjustment coding in one review cycle, reflecting a broader AI push to cut costly coding rework.
Why it matters: Coding accuracy drives risk adjustment payments, and tighter CMS audits make error-free, defensible coding a growing financial priority.
Abridge and Kaiser Permanente launched Care Signals, extending ambient AI beyond visit documentation into the surrounding clinical and administrative work.
Why it matters: It marks ambient AI's shift from note-taking to automating the follow-up work that drives clinician burnout.
Nvidia's new 37-member Open Secure AI Alliance is a warning to hospitals about the security risks of AI tools already embedded in their operations.
Why it matters: AI is spreading fast through hospital workflows, and most security programs were not designed to defend it.
OpenAI has announced the full US rollout of its health-focused AI, expanding consumer access nationwide, according to HIStalk.
Why it matters: Broad access to OpenAI's health AI means more patients will arrive with AI-shaped questions, pressuring providers, vendors, and regulators to adapt.
AI has transformed clinical care, but patients still choose providers using Google searches and star ratings rather than quality data.
Why it matters: How patients pick a doctor shapes outcomes and costs, yet it remains one of healthcare's least data-driven decisions.
Healthcare Dive outlines three capabilities, interoperable data, real-time analytics, and collaboration tools, that increasingly determine success in value-based care.
Why it matters: As providers take on more financial risk, the ability to share data and act on it in real time decides who captures shared savings and who loses money.
Bristol Myers Squibb is the third drugmaker in nine months to claim it is building life sciences' largest NVIDIA AI supercomputer, underscoring a pharma AI infrastructure arms race.
Why it matters: Pharma's rush to claim the biggest AI supercomputer shows how central computing power and NVIDIA have become to drug discovery strategy and corporate positioning.
El Camino Health saw EHR AI use rise 500% in two months after activating every available tool under a strategy CIO Deb Muro calls going 'AI-powered.'
Why it matters: It signals a shift from cautious AI pilots to enterprise-wide activation as health systems bet broad access drives faster clinician adoption.
Mahaska Health CIO Bob Berbeco screens every AI investment against two currencies, time and money, a discipline driven by the thin margins of rural care.
Why it matters: Rural and smaller hospitals face the same AI sales pressure as big systems with far less room for costly mistakes, making ROI-first screening essential.
Dartmouth researchers found AI-drafted patient portal replies often introduce errors and can take physicians longer to edit than writing from scratch.
Why it matters: Cutting inbox burden is a top selling point for clinical AI, and this study suggests the promised time savings may not materialize.
Health system AI leaders are shrugging off a disputed Nature Medicine study that favored general-purpose models over clinical tools, but say the real question of specialized AI's value is unresolved.
Why it matters: As general-purpose AI improves rapidly, health systems must decide whether specialized clinical tools still justify their cost, a choice that will reshape vendor strategy and spending.
Medtronic's April cybersecurity incident exposed Social Security numbers and medical records of more than 72,000 residents in Massachusetts and Vermont, state AG filings show.
Why it matters: Breaches that combine Social Security numbers with medical records heighten fraud and privacy risks and invite growing regulatory scrutiny of healthcare data security.
Oracle Health is advancing an AI-powered EHR overhaul alongside the roughly $37 billion VA implementation, the largest in the U.S., per Becker's.
Why it matters: How Oracle executes its AI EHR redesign and the massive VA rollout will shape competition in the EHR market and federal health IT for years.
Moderna co-founder Kenneth Chien told STAT News the company's mRNA cancer vaccine could be transformative for biotech, highlighting the technology's push beyond infectious disease.
Why it matters: Whether mRNA works against cancer will determine if the platform endures beyond Covid and reshape investor expectations for the sector.
Microsoft's Dragon Copilot now serves more than 100,000 clinicians, reflecting healthcare's shift toward integrated AI documentation tools.
Why it matters: Ambient AI documentation is scaling fast, reshaping how clinicians work and where health systems invest.
Cadence raised $100 million and partnered with Duke Health and Texas Health Resources to expand its chronic disease management platform.
Why it matters: Health systems are increasingly outsourcing chronic care to AI-driven partners to cut costs and stretch limited clinical staff.
A federal judge ruled that a consolidated data breach lawsuit against Oracle Health and eight health systems can proceed, allowing core negligence claims to advance.
Why it matters: The ruling shows that both vendors and the health systems that use them can be held liable when patient data is breached.
A phishing attack on healthcare AI vendor Xsolis exposed data tied to about 1.4 million patients across seven health systems.
Why it matters: Third-party AI vendors holding patient data have become a single point of failure that can expose millions across many hospitals at once.
Definium Therapeutics reported that its LSD drug DT-120 helped major depression patients in its first Phase 3 trial, advancing the psychedelic toward potential FDA approval.
Why it matters: A successful late-stage LSD trial signals psychedelic medicine is maturing toward mainstream regulatory approval after high-profile setbacks.